Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus by Sy, A, McCabe, L, Hudson, E, Ansari, AM, Pedergnana, V, Lin, S-K, Santana, S, Fiorino, M, Ala, A, Stone, B, Smith, M, Nelson, M, Barclay, ST, McPherson, S, Ryder, SD, Collier, J, Barnes, E, Walker, AS, Pett, SL, Cooke, G

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C by Cooke, GS, Pett, S, McCabe, L, Jones, C, Gilson, R, Verma, S, Ryder, SD, Collier, JD, Barclay, ST, Ala, A, Bhagani, S, Nelson, M, Ch'Ng, C, Stone, B, Wiselka, M, Forton, D, McPherson, S, Halford, R, Nguyen, D, Smith, D, Ansari, A, Dennis, E, Hudson, F, Barnes, EJ, Walker, AS

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study by Hamill, V, Wong, S, Benselin, J, Krajden, M, Hayes, PC, Mutimer, D, Yu, A, Dillon, JF, Gelson, W, Velásquez García, HA, Yeung, A, Johnson, P, Barclay, ST, Alvarez, M, Toyoda, H, Agarwal, K, Fraser, A, Bartlett, S, Aldersley, M, Bathgate, A, Binka, M, Richardson, P, Morling, JR, Ryder, SD, Barnes, E

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT by Cooke, GS, Pett, SL, McCabe, L, Jones, C, Gilson, R, Verma, S, Ryder, SD, Collier, JD, Barclay, ST, Ala, A, Bhagani, S, Nelson, M, Ch'Ng, CL, Stone, B, Wiselka, M, Forton, D, McPherson, S, Halford, R, Nguygen, D, Smith, D, Ansari, MA, Ainscough, H, Dennis, E, Hudson, F, Barnes, EJ, Walker, AS